Q1 2025 Earnings Estimate for Eli Lilly and Company (NYSE:LLY) Issued By Zacks Research

Eli Lilly and Company (NYSE:LLY - Free Report) - Investment analysts at Zacks Research cut their Q1 2025 EPS estimates for Eli Lilly and Company in a research report issued on Wednesday, April 17th. Zacks Research analyst K. Shah now forecasts that the company will post earnings of $4.77 per share for the quarter, down from their prior estimate of $4.80. The consensus estimate for Eli Lilly and Company's current full-year earnings is $12.52 per share. Zacks Research also issued estimates for Eli Lilly and Company's Q2 2025 earnings at $4.07 EPS, Q3 2025 earnings at $4.46 EPS, Q4 2025 earnings at $4.50 EPS and FY2025 earnings at $17.80 EPS.

LLY has been the topic of several other reports. Cantor Fitzgerald restated an "overweight" rating and set a $815.00 target price on shares of Eli Lilly and Company in a research report on Monday. TheStreet upgraded shares of Eli Lilly and Company from a "c+" rating to a "b" rating in a research report on Friday, March 8th. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an "overweight" rating in a research report on Friday, March 15th. Barclays upped their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an "overweight" rating in a report on Wednesday, February 7th. Finally, Truist Financial reaffirmed a "buy" rating and issued a $850.00 price target on shares of Eli Lilly and Company in a report on Friday, March 22nd. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $728.05.

Eli Lilly and Company Price Performance

LLY traded down $4.82 on Thursday, hitting $745.95. 1,715,622 shares of the company were exchanged, compared to its average volume of 3,067,708. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The business's fifty day moving average is $764.03 and its 200 day moving average is $657.67. Eli Lilly and Company has a fifty-two week low of $367.35 and a fifty-two week high of $800.78. The firm has a market capitalization of $708.77 billion, a P/E ratio of 129.32, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period in the previous year, the business posted $2.09 earnings per share. The business's revenue was up 28.1% compared to the same quarter last year.

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently added to or reduced their stakes in LLY. Norges Bank acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $5,992,890,000. International Assets Investment Management LLC grew its holdings in Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company's stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares in the last quarter. Moneta Group Investment Advisors LLC grew its holdings in Eli Lilly and Company by 102,752.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company's stock valued at $1,992,374,000 after purchasing an additional 5,440,731 shares in the last quarter. Morgan Stanley grew its holdings in Eli Lilly and Company by 44.1% during the 4th quarter. Morgan Stanley now owns 12,059,204 shares of the company's stock valued at $4,411,740,000 after purchasing an additional 3,691,436 shares in the last quarter. Finally, Imprint Wealth LLC boosted its stake in Eli Lilly and Company by 53,716.8% during the 2nd quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company's stock valued at $175,120,000 after acquiring an additional 1,747,946 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company's stock, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.